自体DC/CIK联合厄洛替尼维持治疗老年晚期非小细胞肺癌的临床疗效分析  

Clinical Effects of Maintenance Therapy Combining Autologous DC/CIK and Erlotinib on Elderly Patients with Advanced Non-small Cell Lung Cancer

作　　者：何志惠[1] 洪涛[1] 苏群豪[1] 曾江正[1] 桑圣刚[2] 

机构地区：[1]海南医学院附属医院血液肿瘤科,海口570102 [2]海南医学院热带与检验学院

出　　处：《肿瘤防治研究》2014年第6期645-648,共4页Cancer Research on Prevention and Treatment

基　　金：海南省重点科技计划资助项目(ZDXM20100046)

摘　　要：目的 观察自体DC/CIK联合厄洛替尼(商品名:特罗凯)维持治疗老年晚期非小细胞肺癌患者的临床意义。方法 将经病理学或细胞学确诊的Ⅲb、Ⅳ期老年(65~85岁)晚期非小细胞肺癌患者42例,经一线含铂两药方案化疗4周期后,疗效达到稳定或以上患者随机分为两组。一组(联合组)给予厄洛替尼及自体DC/CIK生物免疫治疗,另一组(单药组)给予厄洛替尼单药治疗,每月复查评估近期疗效、无肿瘤进展时间及生活质量。结果 两组的疾病控制率分别是85.7%和71.4%(χ2=8.75,P=0.015)。无肿瘤进展时间分别为5.23月、3.57月(P=0.017)。治疗后两组的生活质量均有改善(P=0.001,P=0.008),联合组更为显著(P=0.033)。两组的不良反应主要是皮疹及腹泻,但均能耐受,未作特殊处理自行缓解。结论 厄洛替尼联合自体DC/CIK维持治疗老年晚期非小细胞肺癌能更好地改善患者生活质量,提高疗效及延长生存期。Objective To evaluate the clinical effects of maintenance therapy combining of autologous dentritic cells( DC) and cytokine induced killer cells( CIK cells) and erlotinib on elderly patients with advanced non-small cell lung cancer( NSCLC). Methods Fourty-two elderly patients(65-85 years old) with Stage-Ⅲb and Ⅳ NSCLC underwent 4 cycles of platinum-based two-drug chemotherapy and achieved stable status or much better condition. The patients were randomized into 2 groups, i.e., combination therapy group, which received a biological immunotherapy combining erlotinib and autologous DC/CIK cells, and erlotinib therapy group, which was given erlotinib therapy alone. Efficacy, progression-free survival(PFS) and quality of life were evaluated every month. Results The disease control rates of two groups were 85.7% and 71.4%(χ2=8.75,P=0.015), respectively. The PFS of both groups were 5.23 and 3.57 months respectively(P= 0.017). The quality of life were both improved(P=0.001,P=0.008),especially to the combination group(P=0.033). The untoward reactions of both groups were tolerable rashes and diarrhea. Conclusion The maintenance treatment combining erlotinib and autologous DC/CIK cells can improve quality of life, enhance efficacy and prolong survival time of elderly patients with advanced NSCLC.

关 键 词：非小细胞肺癌 维持治疗 厄洛替尼 树突状细胞 细胞因子诱导的杀伤细胞 

分 类 号：R73[医药卫生—肿瘤]